FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136371246> ?p ?o ?g. }

• W3136371246 endingPage "3860" @default.
• W3136371246 startingPage "3854" @default.
• W3136371246 abstract "To report the interim analysis of the phase II single-arm noninferiority trial, testing the upfront use of dexrazoxane with doxorubicin on progression-free survival (PFS) and cardiac function in soft-tissue sarcoma (STS).Patients with metastatic or unresectable STS who were candidates for first-line treatment with doxorubicin were deemed eligible. An interim analysis was initiated after 33 of 65 patients were enrolled. Using the historical control of 4.6 months PFS for doxorubicin in the front-line setting, we tested whether the addition of dexrazoxane affected the efficacy of doxorubicin in STS. The study was powered so that a decrease of PFS to 3.7 months would be considered noninferior. Secondary aims included cardiac-related mortality, incidence of heart failure/cardiomyopathy, and expansion of cardiac monitoring parameters including three-dimensional echocardiography. Patients were allowed to continue on doxorubicin beyond 600 mg/m2 if they were deriving benefit and were not demonstrating evidence of symptomatic cardiac dysfunction.At interim analysis, upfront use of dexrazoxane with doxorubicin demonstrated a PFS of 8.4 months (95% confidence interval: 5.1-11.2 months). Only 3 patients were removed from study for cardiotoxicity, all on > 600 mg/m2 doxorubicin. No patients required cardiac hospitalization or had new, persistent cardiac dysfunction with left ventricular ejection fraction remaining below 50%. The median administered doxorubicin dose was 450 mg/m2 (interquartile range, 300-750 mg/m2).At interim analysis, dexrazoxane did not reduce PFS in patients with STS treated with doxorubicin. Involvement of cardio-oncologists is beneficial for the monitoring and safe use of high-dose anthracyclines in STS.See related commentary by Benjamin and Minotti, p. 3809." @default.
• W3136371246 created "2021-03-29" @default.
• W3136371246 creator A5003432789 @default.
• W3136371246 creator A5014249119 @default.
• W3136371246 creator A5019154098 @default.
• W3136371246 creator A5019603606 @default.
• W3136371246 creator A5028104092 @default.
• W3136371246 creator A5036374373 @default.
• W3136371246 creator A5036526586 @default.
• W3136371246 creator A5037690587 @default.
• W3136371246 creator A5045593578 @default.
• W3136371246 creator A5046737949 @default.
• W3136371246 creator A5052934132 @default.
• W3136371246 creator A5059572789 @default.
• W3136371246 creator A5061407065 @default.
• W3136371246 creator A5062948390 @default.
• W3136371246 creator A5064641404 @default.
• W3136371246 creator A5067015993 @default.
• W3136371246 creator A5069227756 @default.
• W3136371246 creator A5089302374 @default.
• W3136371246 date "2021-03-25" @default.
• W3136371246 modified "2023-10-14" @default.
• W3136371246 title "Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma" @default.
• W3136371246 cites W1833330468 @default.
• W3136371246 cites W2005384806 @default.
• W3136371246 cites W2010183849 @default.
• W3136371246 cites W2022286593 @default.
• W3136371246 cites W2033538830 @default.
• W3136371246 cites W2043254982 @default.
• W3136371246 cites W2051006637 @default.
• W3136371246 cites W2074934283 @default.
• W3136371246 cites W2091238429 @default.
• W3136371246 cites W2099814384 @default.
• W3136371246 cites W2104238143 @default.
• W3136371246 cites W2104615664 @default.
• W3136371246 cites W2109634728 @default.
• W3136371246 cites W2112196039 @default.
• W3136371246 cites W2124624517 @default.
• W3136371246 cites W2125657259 @default.
• W3136371246 cites W2135890654 @default.
• W3136371246 cites W2136344041 @default.
• W3136371246 cites W2146035745 @default.
• W3136371246 cites W2181200527 @default.
• W3136371246 cites W2298838354 @default.
• W3136371246 cites W2413552560 @default.
• W3136371246 cites W2516857894 @default.
• W3136371246 cites W2520149112 @default.
• W3136371246 cites W2550780054 @default.
• W3136371246 cites W2653632515 @default.
• W3136371246 cites W2911752236 @default.
• W3136371246 cites W2952822323 @default.
• W3136371246 cites W3014683777 @default.
• W3136371246 cites W4298043198 @default.
• W3136371246 doi "https://doi.org/10.1158/1078-0432.ccr-20-4621" @default.
• W3136371246 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8282681" @default.
• W3136371246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33766818" @default.
• W3136371246 hasPublicationYear "2021" @default.
• W3136371246 type Work @default.
• W3136371246 sameAs 3136371246 @default.
• W3136371246 citedByCount "8" @default.
• W3136371246 countsByYear W31363712462021 @default.
• W3136371246 countsByYear W31363712462022 @default.
• W3136371246 countsByYear W31363712462023 @default.
• W3136371246 crossrefType "journal-article" @default.
• W3136371246 hasAuthorship W3136371246A5003432789 @default.
• W3136371246 hasAuthorship W3136371246A5014249119 @default.
• W3136371246 hasAuthorship W3136371246A5019154098 @default.
• W3136371246 hasAuthorship W3136371246A5019603606 @default.
• W3136371246 hasAuthorship W3136371246A5028104092 @default.
• W3136371246 hasAuthorship W3136371246A5036374373 @default.
• W3136371246 hasAuthorship W3136371246A5036526586 @default.
• W3136371246 hasAuthorship W3136371246A5037690587 @default.
• W3136371246 hasAuthorship W3136371246A5045593578 @default.
• W3136371246 hasAuthorship W3136371246A5046737949 @default.
• W3136371246 hasAuthorship W3136371246A5052934132 @default.
• W3136371246 hasAuthorship W3136371246A5059572789 @default.
• W3136371246 hasAuthorship W3136371246A5061407065 @default.
• W3136371246 hasAuthorship W3136371246A5062948390 @default.
• W3136371246 hasAuthorship W3136371246A5064641404 @default.
• W3136371246 hasAuthorship W3136371246A5067015993 @default.
• W3136371246 hasAuthorship W3136371246A5069227756 @default.
• W3136371246 hasAuthorship W3136371246A5089302374 @default.
• W3136371246 hasBestOaLocation W31363712461 @default.
• W3136371246 hasConcept C121608353 @default.
• W3136371246 hasConcept C126322002 @default.
• W3136371246 hasConcept C136948725 @default.
• W3136371246 hasConcept C141071460 @default.
• W3136371246 hasConcept C143998085 @default.
• W3136371246 hasConcept C2776694085 @default.
• W3136371246 hasConcept C2776802502 @default.
• W3136371246 hasConcept C2778198053 @default.
• W3136371246 hasConcept C2778233292 @default.
• W3136371246 hasConcept C2778629024 @default.
• W3136371246 hasConcept C2779720357 @default.
• W3136371246 hasConcept C2781303535 @default.
• W3136371246 hasConcept C530470458 @default.
• W3136371246 hasConcept C535046627 @default.
• W3136371246 hasConcept C61943457 @default.

• next